Cross-source identity
National Provider Identifier 1073834370 as it appears in every federal dataset Fonteum holds. Each row is a distinct public source; the chip carries the source and the snapshot date behind that field — the record-level form of the source-provenanced graph.
| Federal source | Key | What it provides | Provenance |
|---|
| CMS NPPES | NPI 1073834370 | Registry identity — psychiatrist, taxonomy 2084P0800X | Source:CMS NPPESSnapshot 2026-05-06 |
| CMS Open Payments | NPI 1073834370 | 161 industry-payment records, 2024 | Source:CMS Open PaymentsSnapshot PY2024 |
| CMS Medicare Part D | NPI 1073834370 | 38 drugs prescribed, 2024 | Source:CMS Part DSnapshot DY2024 |
| Fonteum entity graph | entity 7d96cd6b… | Canonical resolved node · 4 identifier(s) · 5 edge(s) | Source:Entity graphSnapshot 2026-06-11 |
Industry payments
Payments and transfers of value this clinician received from drug and device manufacturers, disclosed under the Physician Payments Sunshine Act. A payment is a disclosure, not a judgment.
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $34,876 | 15 |
| Consulting Fee | $5,738 | 1 |
| Food and Beverage | $2,746 | 122 |
| Travel and Lodging | $2,201 | 22 |
| Education |
| Manufacturer | Amount | Records |
|---|---|---|
| Neurocrine Biosciences, Inc. | $27,524 | 36 |
| Abbvie Inc. | $16,581 | 71 |
| Teva Pharmaceuticals Usa, Inc. | $380 |
Prescribing
Prescriptions written under Medicare Part D, aggregated by drug across the program. Totals reflect claims paid, not patients treated.
| Drug | Claims | Drug cost |
|---|---|---|
| Ingrezza(Valbenazine Tosylate) | 26 | $218,198 |
| Rexulti(Brexpiprazole) | 17 | $33,352 |
| Trintellix(Vortioxetine Hydrobromide) | 25 | $21,463 |
| Aripiprazole | 19 | $7,449 |
| Lurasidone Hcl | 31 | $6,544 |
Beneficiary counts below 11 are suppressed by CMS — the total shown is a lower bound.
Quality
CMS Quality Payment Program Merit-based Incentive Payment System (MIPS) final score, where this clinician participated. Absence of a score is not a quality signal — many clinicians report through a group or are exempt.
Enrollment & sanctions
Screening aid — re-confirm any match against the issuing list before acting. A clean result means no record was found in the federal OIG LEIE or the state Medicaid lists Fonteum currently holds (NY, OH, GA), not a guarantee that none exists elsewhere. Not a legal or credentialing certification.
Ownership & affiliations
One-hop relationships in the resolved entity graph — chain membership, ownership, and operation edges, each backed by a federal source row. Most individual clinicians carry none; edges populate for owners and organizations as the Lane D backfill runs.
| Relationship | Entity | Source |
|---|---|---|
| ← pays | Janssen Pharmaceuticals, Inc (NJ) | cms_open_payments |
| ← pays | Neos Therapeutics, Lp (CO) | cms_open_payments |
| ← pays | Corium, Llc (MA) | cms_open_payments |
| ← pays | E.R. Squibb & Sons, L.L.C. (NJ) | cms_open_payments |
| ← pays | Abbvie Inc. (IL) | cms_open_payments |
| 1 |
| 3 |
| Iti, Inc. (D/B/A Intra-Cellular Therapies, Inc.) | $320 | 18 |
| E.R. Squibb & Sons, L.L.C. | $183 | 9 |